Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Nicolas, Janus"'
Publikováno v:
Néphrologie & Thérapeutique. 17:553-563
The renal toxicity of anticancer drugs is a clinical challenge because of the intrinsic toxicity of some anticancer drugs and because the cancer itself. Indeed, cancer patients are exposed to all types of renal disorders (obstructive, functional, org
Publikováno v:
Supportive Care in Cancer. 30:2919-2931
Updated clinical practice guidelines recommend the long-term use of low-molecular-weight heparins or direct oral anticoagulants as the preferred option for the treatment of cancer-associated thrombosis (CAT), using a personalized approach matching th
Autor:
Blandine, Aloy, Nicolas, Janus, Corine, Isnard-Bagnis, Gilbert, Deray, Vincent, Launay-Vacher
Publikováno v:
Nephrologietherapeutique. 17(7)
The renal toxicity of anticancer drugs is a clinical challenge because of the intrinsic toxicity of some anticancer drugs and because the cancer itself. Indeed, cancer patients are exposed to all types of renal disorders (obstructive, functional, org
Publikováno v:
Néphrologie & Thérapeutique. 14:484-490
The development of interventional radiology techniques regularly exposes patients to the potential renal toxocity of iodinated contrast media. Faced with this risk of nephrotoxicity, gadolinium-based contrast agents have long been considered as a saf
Publikováno v:
Cancers
Cancers, MDPI, 2020, 12 (4), pp.917. ⟨10.3390/cancers12040917⟩
Cancers, Vol 12, Iss 917, p 917 (2020)
Cancers, MDPI, 2020, 12 (4), pp.917. ⟨10.3390/cancers12040917⟩
Cancers, Vol 12, Iss 917, p 917 (2020)
International audience; Direct oral anticoagulants (DOAC) are now recommended for the treatment of cancer-associated thrombosis (CAT) based on the results of dedicated trials demonstrating that DOAC are non-inferior to low molecular weight heparins i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ec37c0056698f3b235a59eaffa7e47c
https://hal.sorbonne-universite.fr/hal-02863843/document
https://hal.sorbonne-universite.fr/hal-02863843/document
Autor:
Nicolas Janus, Henrick Thoning, Pieter Willem Kamphuisen, Rupert Bauersachs, Randall Leeder, Alok A. Khorana, Agnes Y.Y. Lee
Publikováno v:
Blood. 138:4273-4273
Introduction In patients with hematological cancers, the high risk of bleeding raises serious concerns when anticoagulant therapy is initiated for treatment of acute venous thromboembolism (VTE). In the CATCH trial, we showed that tinzaparin is assoc
Autor:
Vincent Launay-Vacher, Nicolas Janus
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 13:617-623
The increased incidence of cancer in hemodialysis patients has been discussed since the mid-70s. Today, physicians regularly encounter situations where they must manage the prescription of anticancer drugs in hemodialysis patients. Areas covered: Hem
Publikováno v:
Journal des Maladies Vasculaires. 41:389-395
Anticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk
Autor:
Nicolas Janus, I. Elalamy
Publikováno v:
Thrombosis Research. 200:S70
Autor:
Nicolas Janus
Publikováno v:
Blood. 136:15-15
INTRODUCTION AND AIMS: Anaemia is very common in cancer patients. However, the impact of anaemia in venous thromboembolic (VTE) patients on the risk of bleeding is not well-known. Consequently, the question of the impact of anaemia in cancer-associat